Relapse of psoriasis after cyclin‐dependent kinase 4 and 6 inhibitor: An emerging signalling pathway in cancer treatment and psoriasis

Journal of the European Academy of Dermatology and VenereologyVolume 37, Issue 9 p. e1134-e1135 LETTER TO THE EDITOR Relapse of psoriasis after cyclin-dependent kinase 4 and 6 inhibitor: An emerging signalling pathway in cancer treatment and psoriasis Yi-An Chen, Corresponding Author Yi-An Chen [email protected] orcid.org/0009-0003-8892-1145 Department of Dermatology, Cathay General Hospital, Taipei, Taiwan Department of Dermatology, Hsinchu Cathay General Hospital, Hsinchu, Taiwan Correspondence Yi-An Chen, No. 280, Sec. 4, Renai Road, Taipei 106, Taiwan. Email: [email protected]Search for more papers by this authorYa-Tang Yang, Ya-Tang Yang orcid.org/0000-0002-5604-9968 Department of Dermatology, Cathay General Hospital, Taipei, TaiwanSearch for more papers by this author Yi-An Chen, Corresponding Author Yi-An Chen [email protected] orcid.org/0009-0003-8892-1145 Department of Dermatology, Cathay General Hospital, Taipei, Taiwan Department of Dermatology, Hsinchu Cathay General Hospital, Hsinchu, Taiwan Correspondence Yi-An Chen, No. 280, Sec. 4, Renai Road, Taipei 106, Taiwan. Email: [email protected]Search for more papers by this authorYa-Tang Yang, Ya-Tang Yang orcid.org/0000-0002-5604-9968 Department of Dermatology, Cathay General Hospital, Taipei, TaiwanSearch for more papers by this author First published: 27 April 2023 https://doi.org/10.1111/jdv.19148Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020; 395: 817–27. 2Henri P, Prevel C, Pellerano M, Lacotte J, Stoebner PE, Morris MC, et al. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity. Br J Dermatol. 2020; 182: 678–89. 3Sun S, Zhang X, Xu M, Zhang F, Tian F, Cui J, et al. Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes. Cell Death Dis. 2019; 10: 274. 4Gautam P, Maenner S, Cailotto F, Reboul P, Labialle S, Jouzeau JY, et al. Emerging role of IκBζ in inflammation: emphasis on psoriasis. Clin Transl Med. 2022; 12:e1032. 5Müller A, Dickmanns A, Resch C, Schäkel K, Hailfinger S, Dobbelstein M, et al. The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. J Clin Invest. 2020; 130: 5765–81. Volume37, Issue9September 2023Pages e1134-e1135 ReferencesRelatedInformation